ACTINOGEN MEDICAL LIMITED - Announcements

3.70%

2.8¢

Market Cap $88.91M

Healthcare Biotechnology

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel... Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long term cognitive health.More

Corporate Spotlight

Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives.
View the full Corporate Spotlight

Actinogen reaches 100th participant milestone

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

ACW	ACW pharmacokinetics trial success	PRICE SENSITIVE	26/08/25	239.79KB	Share
ACW	ACW FY2025 results - accelerating Alzheimers pivotal trial	PRICE SENSITIVE	25/08/25	256.71KB	Share
ACW	ACW Appendix 4E and 2025 annual report	PRICE SENSITIVE	25/08/25	5.81MB	Share
ACW	Actinogen June 2025 quarterly activity report & Appendix 4C	PRICE SENSITIVE	30/07/25	603.58KB	Share
ACW	ACW accesses up to $13.8m in non-dilutive R&D tax funding	PRICE SENSITIVE	30/06/25	262.03KB	Share
ACW	ACW 100th AD trial participant & interim analysis timeline	PRICE SENSITIVE	30/06/25	269.25KB	Share
ACW	Actinogen March 2025 quarterly activity report & Appendix 4C	PRICE SENSITIVE	30/04/25	512.41KB	Share
ACW	ACW conducts Type C meeting with FDA regarding depression	PRICE SENSITIVE	27/03/25	236.28KB	Share
ACW	ACW HY25 results Advancing to latestage clinical development	PRICE SENSITIVE	24/02/25	274.84KB	Share
ACW	Actinogen HY2025 financial report and Appendix 4D	PRICE SENSITIVE	24/02/25	1.9MB	Share
ACW	Peer-reviewed clinpharm manuscript published	PRICE SENSITIVE	06/02/25	253.79KB	Share
ACW	ACW December 2024 quarterly activity report & Appendix 4C	PRICE SENSITIVE	29/01/25	558.42KB	Share
ACW	ACW randomizes first US participant in Alzheimers trial	PRICE SENSITIVE	09/12/24	239.69KB	Share
ACW	Actinogen receives $9.0 million R&D tax incentive rebate	PRICE SENSITIVE	12/11/24	210.91KB	Share
ACW	ACW September 2024 quarterly activity report & Appendix 4C	PRICE SENSITIVE	30/10/24	573.58KB	Share
ACW	$3.0 million share purchase plan closes 1.3x oversubscribed	PRICE SENSITIVE	10/10/24	243.9KB	Share
ACW	ACW $11.1m capital raising to accelerate Alzheimers trial	PRICE SENSITIVE	18/09/24	1.6MB	Share
ACW	Trading Halt	PRICE SENSITIVE	16/09/24	661.05KB	Share
ACW	Pause in Trading	PRICE SENSITIVE	16/09/24	116.14KB	Share
ACW	ACW FY2024 results, advancing into late-stage trials	PRICE SENSITIVE	30/08/24	257.96KB	Share
ACW	ACW Appendix 4E and 2024 Annual Report	PRICE SENSITIVE	30/08/24	5.91MB	Share
ACW	ACW updated depression trial results and implications	PRICE SENSITIVE	26/08/24	258.85KB	Share
ACW	ACW XanaCIDD phase 2a trial topline results	PRICE SENSITIVE	12/08/24	1.1MB	Share
ACW	Trading Halt	PRICE SENSITIVE	08/08/24	664.71KB	Share
ACW	ACW June 2024 quarterly activity report & Appendix 4C	PRICE SENSITIVE	22/07/24	590.63KB	Share
ACW	ACW XanaCIDD depression trial results expected early August	PRICE SENSITIVE	02/07/24	248.15KB	Share
ACW	Positive Xanamem biomarker trial published in Jnl Alz Dis	PRICE SENSITIVE	26/06/24	317.48KB	Share
ACW	ACW Oversubscribed $3.9 million entitlement offer completed	PRICE SENSITIVE	05/06/24	218.56KB	Share
ACW	Actinogen entitlement offer closed and oversubscribed	PRICE SENSITIVE	30/05/24	240.11KB	Share
ACW	Prospectus - Non-renounceable Entitlement Offer	PRICE SENSITIVE	07/05/24	470.52KB	Share
ACW	Actinogen announces capital raising of up to $8.9 million	PRICE SENSITIVE	03/05/24	2.68MB	Share
ACW	Trading Halt	PRICE SENSITIVE	01/05/24	333.62KB	Share
ACW	ACW March 2024 quarterly activity report & Appendix 4C	PRICE SENSITIVE	30/04/24	592.09KB	Share
ACW	ACW completes cognition & depression phase 2 trial enrolment	PRICE SENSITIVE	22/04/24	244.8KB	Share
ACW	First patient treated in ACW XanaMIA ph 2b Alzheimers trial	PRICE SENSITIVE	15/04/24	238.21KB	Share
ACW	Actinogen HY2024 financial results two key phase 2 trial	PRICE SENSITIVE	26/02/24	256.58KB	Share
ACW	Actinogen HY2024 financial report and Appendix 4D	PRICE SENSITIVE	26/02/24	2.75MB	Share
ACW	Response to ASX Aware Query	PRICE SENSITIVE	20/02/24	934.62KB	Share
ACW	Actinogen awarded UK Innovation Passport for Xanamem	PRICE SENSITIVE	15/02/24	242.2KB	Share
ACW	ACW December 2023 quarterly activity report & Appendix 4C	PRICE SENSITIVE	30/01/24	510KB	Share
ACW	Actinogen receives $4.8 million R&D tax incentive rebate	PRICE SENSITIVE	28/11/23	224.74KB	Share
ACW	Actinogen September quarterly activity report & Appendix 4C	PRICE SENSITIVE	16/10/23	511.35KB	Share
ACW	Actinogen enhances XanaMIA Phase 2b Alzheimers trial	PRICE SENSITIVE	26/09/23	219.7KB	Share
ACW	Actinogen closes successful $10 million rights issue offer	PRICE SENSITIVE	07/09/23	218.02KB	Share
ACW	Actinogen FY2023 results, following the science	PRICE SENSITIVE	30/08/23	269.85KB	Share
ACW	ACW Appendix 4E and 2023 Annual Report	PRICE SENSITIVE	30/08/23	4.11MB	Share
ACW	ACW secures further $0.5m rights issue shortfall commitment	PRICE SENSITIVE	30/08/23	224.98KB	Share
ACW	ACW secures shortfall commitments of $4.56m for rights issue	PRICE SENSITIVE	15/08/23	222.88KB	Share
ACW	Entitlement Offer Prospectus	PRICE SENSITIVE	08/08/23	1.26MB	Share
ACW	Actinogen announces $10 million rights offer	PRICE SENSITIVE	02/08/23	259.74KB	Share
ACW	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	31/07/23	330.43KB	Share
ACW	Trading Halt	PRICE SENSITIVE	31/07/23	642.62KB	Share
ACW	ACW AD trial amendment and Clinical Science Forum slides	PRICE SENSITIVE	24/05/23	1.69MB	Share
ACW	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	24/04/23	325.71KB	Share
ACW	Appendix 4D & Half-Year Financial Statements	PRICE SENSITIVE	22/02/23	1.33MB	Share
ACW	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	30/01/23	389.51KB	Share
ACW	FDA agrees to six-month Phase 2b Alzheimers Disease Trial	PRICE SENSITIVE	22/12/22	235.52KB	Share
ACW	First patient treated in XanaCIDD Phase 2 Depression Trial	PRICE SENSITIVE	08/12/22	230.87KB	Share
ACW	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	28/10/22	489.86KB	Share
ACW	R&D tax incentive rebate received	PRICE SENSITIVE	20/10/22	204.95KB	Share
ACW	ACW clinical biomarker study webcast presentation	PRICE SENSITIVE	10/10/22	2.4MB	Share
ACW	ACW announces positive Alzheimers Disease clinical results	PRICE SENSITIVE	10/10/22	300.23KB	Share
ACW	Trading Halt	PRICE SENSITIVE	06/10/22	272.6KB	Share
ACW	Actinogen FY22 Results - Accelerating Clinical Development	PRICE SENSITIVE	25/08/22	254.15KB	Share
ACW	ACW Appendix 4E and 2022 Annual Report	PRICE SENSITIVE	25/08/22	4.92MB	Share
ACW	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	28/07/22	348.85KB	Share
ACW	ACW announces Phase 2 trial designs for AD & MDD	PRICE SENSITIVE	14/06/22	556.64KB	Share
ACW	Actinogen trial results & strategic update presentation	PRICE SENSITIVE	04/05/22	2.29MB	Share
ACW	Actinogen prioritizes Alzheimers Disease & Depression	PRICE SENSITIVE	04/05/22	243.81KB	Share
ACW	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	28/04/22	814.14KB	Share
ACW	ACW positive XanaMIA results webcast slide presentation	PRICE SENSITIVE	27/04/22	2.07MB	Share
ACW	ACW announces positive XanaMIA results for Xanamem	PRICE SENSITIVE	27/04/22	250.85KB	Share
ACW	Trading Halt	PRICE SENSITIVE	22/04/22	679.48KB	Share
ACW	Appendix 4D & Half-Year Financial Statements	PRICE SENSITIVE	24/02/22	975.13KB	Share
ACW	Actinogen XanaMIA Part A trial results expected in April	PRICE SENSITIVE	11/02/22	256.29KB	Share
ACW	Actinogen appoints XanaFX Phase 2 trial manager	PRICE SENSITIVE	09/02/22	259.28KB	Share
ACW	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	28/01/22	496.77KB	Share
ACW	Capital Raising Completion	PRICE SENSITIVE	20/12/21	236KB	Share
ACW	ACW Strategic Collaboration with Oxford Uni Researchers	PRICE SENSITIVE	07/12/21	180.98KB	Share
ACW	XanaMIA Part A trial achieves target enrolment	PRICE SENSITIVE	29/11/21	204.1KB	Share
ACW	Strategic Update & Capital Raising Investor Presentation	PRICE SENSITIVE	25/11/21	6.5MB	Share
ACW	Program Expansion & Capital Raising	PRICE SENSITIVE	25/11/21	271.26KB	Share
ACW	Trading Halt	PRICE SENSITIVE	23/11/21	343.76KB	Share
ACW	ACW announces open IND for Phase 2 Fragile X trial & LOI	PRICE SENSITIVE	09/11/21	236.09KB	Share
ACW	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	20/10/21	409.13KB	Share
ACW	R&D Tax Incentive Rebate received of A$1.435 million	PRICE SENSITIVE	13/10/21	198.91KB	Share
ACW	Actinogen Medical FY21 Results- Progressing the Pipeline	PRICE SENSITIVE	30/08/21	233.75KB	Share
ACW	Appendix 4E & Annual Report	PRICE SENSITIVE	30/08/21	2.74MB	Share
ACW	Actinogen completes global patent family grant	PRICE SENSITIVE	23/08/21	194.63KB	Share
ACW	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	22/07/21	284.43KB	Share
ACW	First Patient Enrolled in XanaMIA trial	PRICE SENSITIVE	15/07/21	187.34KB	Share
ACW	Actinogen receives positive Pre-IND FDA advice for FXS	PRICE SENSITIVE	23/06/21	174.43KB	Share
ACW	Clinical progress for XanaMIA trial	PRICE SENSITIVE	21/06/21	137.28KB	Share
ACW	Actinogen Ethics Committee approval for XanaMIA study	PRICE SENSITIVE	02/06/21	162.47KB	Share
ACW	Response to ASX Price Query	PRICE SENSITIVE	24/05/21	291.5KB	Share
ACW	Strategic Update & Teleconference Call Notification	PRICE SENSITIVE	21/04/21	3.02MB	Share
ACW	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	21/04/21	285.3KB	Share
ACW	Actinogen CEO assumes Managing Director position	PRICE SENSITIVE	24/03/21	159.22KB	Share
ACW	Actinogen appoints Dr Steven Gourlay as CEO	PRICE SENSITIVE	15/03/21	216.74KB	Share
ACW	Appendix 4D & Half-Year Financial Statements	PRICE SENSITIVE	24/02/21	453.53KB	Share

ACW ACW pharmacokinetics trial success
26/08/25	PRICE SENSITIVE	239.79KB	Share
ACW ACW FY2025 results - accelerating Alzheimers pivotal trial
25/08/25	PRICE SENSITIVE	256.71KB	Share
ACW ACW Appendix 4E and 2025 annual report
25/08/25	PRICE SENSITIVE	5.81MB	Share
ACW Actinogen June 2025 quarterly activity report & Appendix 4C
30/07/25	PRICE SENSITIVE	603.58KB	Share
ACW ACW accesses up to $13.8m in non-dilutive R&D tax funding
30/06/25	PRICE SENSITIVE	262.03KB	Share
ACW ACW 100th AD trial participant & interim analysis timeline
30/06/25	PRICE SENSITIVE	269.25KB	Share
ACW Actinogen March 2025 quarterly activity report & Appendix 4C
30/04/25	PRICE SENSITIVE	512.41KB	Share
ACW ACW conducts Type C meeting with FDA regarding depression
27/03/25	PRICE SENSITIVE	236.28KB	Share
ACW ACW HY25 results Advancing to latestage clinical development
24/02/25	PRICE SENSITIVE	274.84KB	Share
ACW Actinogen HY2025 financial report and Appendix 4D
24/02/25	PRICE SENSITIVE	1.9MB	Share
ACW Peer-reviewed clinpharm manuscript published
06/02/25	PRICE SENSITIVE	253.79KB	Share
ACW ACW December 2024 quarterly activity report & Appendix 4C
29/01/25	PRICE SENSITIVE	558.42KB	Share
ACW ACW randomizes first US participant in Alzheimers trial
09/12/24	PRICE SENSITIVE	239.69KB	Share
ACW Actinogen receives $9.0 million R&D tax incentive rebate
12/11/24	PRICE SENSITIVE	210.91KB	Share
ACW ACW September 2024 quarterly activity report & Appendix 4C
30/10/24	PRICE SENSITIVE	573.58KB	Share
ACW $3.0 million share purchase plan closes 1.3x oversubscribed
10/10/24	PRICE SENSITIVE	243.9KB	Share
ACW ACW $11.1m capital raising to accelerate Alzheimers trial
18/09/24	PRICE SENSITIVE	1.6MB	Share
ACW Trading Halt
16/09/24	PRICE SENSITIVE	661.05KB	Share
ACW Pause in Trading
16/09/24	PRICE SENSITIVE	116.14KB	Share
ACW ACW FY2024 results, advancing into late-stage trials
30/08/24	PRICE SENSITIVE	257.96KB	Share
ACW ACW Appendix 4E and 2024 Annual Report
30/08/24	PRICE SENSITIVE	5.91MB	Share
ACW ACW updated depression trial results and implications
26/08/24	PRICE SENSITIVE	258.85KB	Share
ACW ACW XanaCIDD phase 2a trial topline results
12/08/24	PRICE SENSITIVE	1.1MB	Share
ACW Trading Halt
08/08/24	PRICE SENSITIVE	664.71KB	Share
ACW ACW June 2024 quarterly activity report & Appendix 4C
22/07/24	PRICE SENSITIVE	590.63KB	Share
ACW ACW XanaCIDD depression trial results expected early August
02/07/24	PRICE SENSITIVE	248.15KB	Share
ACW Positive Xanamem biomarker trial published in Jnl Alz Dis
26/06/24	PRICE SENSITIVE	317.48KB	Share
ACW ACW Oversubscribed $3.9 million entitlement offer completed
05/06/24	PRICE SENSITIVE	218.56KB	Share
ACW Actinogen entitlement offer closed and oversubscribed
30/05/24	PRICE SENSITIVE	240.11KB	Share
ACW Prospectus - Non-renounceable Entitlement Offer
07/05/24	PRICE SENSITIVE	470.52KB	Share
ACW Actinogen announces capital raising of up to $8.9 million
03/05/24	PRICE SENSITIVE	2.68MB	Share
ACW Trading Halt
01/05/24	PRICE SENSITIVE	333.62KB	Share
ACW ACW March 2024 quarterly activity report & Appendix 4C
30/04/24	PRICE SENSITIVE	592.09KB	Share
ACW ACW completes cognition & depression phase 2 trial enrolment
22/04/24	PRICE SENSITIVE	244.8KB	Share
ACW First patient treated in ACW XanaMIA ph 2b Alzheimers trial
15/04/24	PRICE SENSITIVE	238.21KB	Share
ACW Actinogen HY2024 financial results two key phase 2 trial
26/02/24	PRICE SENSITIVE	256.58KB	Share
ACW Actinogen HY2024 financial report and Appendix 4D
26/02/24	PRICE SENSITIVE	2.75MB	Share
ACW Response to ASX Aware Query
20/02/24	PRICE SENSITIVE	934.62KB	Share
ACW Actinogen awarded UK Innovation Passport for Xanamem
15/02/24	PRICE SENSITIVE	242.2KB	Share
ACW ACW December 2023 quarterly activity report & Appendix 4C
30/01/24	PRICE SENSITIVE	510KB	Share
ACW Actinogen receives $4.8 million R&D tax incentive rebate
28/11/23	PRICE SENSITIVE	224.74KB	Share
ACW Actinogen September quarterly activity report & Appendix 4C
16/10/23	PRICE SENSITIVE	511.35KB	Share
ACW Actinogen enhances XanaMIA Phase 2b Alzheimers trial
26/09/23	PRICE SENSITIVE	219.7KB	Share
ACW Actinogen closes successful $10 million rights issue offer
07/09/23	PRICE SENSITIVE	218.02KB	Share
ACW Actinogen FY2023 results, following the science
30/08/23	PRICE SENSITIVE	269.85KB	Share
ACW ACW Appendix 4E and 2023 Annual Report
30/08/23	PRICE SENSITIVE	4.11MB	Share
ACW ACW secures further $0.5m rights issue shortfall commitment
30/08/23	PRICE SENSITIVE	224.98KB	Share
ACW ACW secures shortfall commitments of $4.56m for rights issue
15/08/23	PRICE SENSITIVE	222.88KB	Share
ACW Entitlement Offer Prospectus
08/08/23	PRICE SENSITIVE	1.26MB	Share
ACW Actinogen announces $10 million rights offer
02/08/23	PRICE SENSITIVE	259.74KB	Share
ACW Quarterly Activity Report & Appendix 4C
31/07/23	PRICE SENSITIVE	330.43KB	Share
ACW Trading Halt
31/07/23	PRICE SENSITIVE	642.62KB	Share
ACW ACW AD trial amendment and Clinical Science Forum slides
24/05/23	PRICE SENSITIVE	1.69MB	Share
ACW Quarterly Activity Report & Appendix 4C
24/04/23	PRICE SENSITIVE	325.71KB	Share
ACW Appendix 4D & Half-Year Financial Statements
22/02/23	PRICE SENSITIVE	1.33MB	Share
ACW Quarterly Activity Report & Appendix 4C
30/01/23	PRICE SENSITIVE	389.51KB	Share
ACW FDA agrees to six-month Phase 2b Alzheimers Disease Trial
22/12/22	PRICE SENSITIVE	235.52KB	Share
ACW First patient treated in XanaCIDD Phase 2 Depression Trial
08/12/22	PRICE SENSITIVE	230.87KB	Share
ACW Quarterly Activity Report & Appendix 4C
28/10/22	PRICE SENSITIVE	489.86KB	Share
ACW R&D tax incentive rebate received
20/10/22	PRICE SENSITIVE	204.95KB	Share
ACW ACW clinical biomarker study webcast presentation
10/10/22	PRICE SENSITIVE	2.4MB	Share
ACW ACW announces positive Alzheimers Disease clinical results
10/10/22	PRICE SENSITIVE	300.23KB	Share
ACW Trading Halt
06/10/22	PRICE SENSITIVE	272.6KB	Share
ACW Actinogen FY22 Results - Accelerating Clinical Development
25/08/22	PRICE SENSITIVE	254.15KB	Share
ACW ACW Appendix 4E and 2022 Annual Report
25/08/22	PRICE SENSITIVE	4.92MB	Share
ACW Quarterly Activity Report & Appendix 4C
28/07/22	PRICE SENSITIVE	348.85KB	Share
ACW ACW announces Phase 2 trial designs for AD & MDD
14/06/22	PRICE SENSITIVE	556.64KB	Share
ACW Actinogen trial results & strategic update presentation
04/05/22	PRICE SENSITIVE	2.29MB	Share
ACW Actinogen prioritizes Alzheimers Disease & Depression
04/05/22	PRICE SENSITIVE	243.81KB	Share
ACW Quarterly Activity Report & Appendix 4C
28/04/22	PRICE SENSITIVE	814.14KB	Share
ACW ACW positive XanaMIA results webcast slide presentation
27/04/22	PRICE SENSITIVE	2.07MB	Share
ACW ACW announces positive XanaMIA results for Xanamem
27/04/22	PRICE SENSITIVE	250.85KB	Share
ACW Trading Halt
22/04/22	PRICE SENSITIVE	679.48KB	Share
ACW Appendix 4D & Half-Year Financial Statements
24/02/22	PRICE SENSITIVE	975.13KB	Share
ACW Actinogen XanaMIA Part A trial results expected in April
11/02/22	PRICE SENSITIVE	256.29KB	Share
ACW Actinogen appoints XanaFX Phase 2 trial manager
09/02/22	PRICE SENSITIVE	259.28KB	Share
ACW Quarterly Activity Report & Appendix 4C
28/01/22	PRICE SENSITIVE	496.77KB	Share
ACW Capital Raising Completion
20/12/21	PRICE SENSITIVE	236KB	Share
ACW ACW Strategic Collaboration with Oxford Uni Researchers
07/12/21	PRICE SENSITIVE	180.98KB	Share
ACW XanaMIA Part A trial achieves target enrolment
29/11/21	PRICE SENSITIVE	204.1KB	Share
ACW Strategic Update & Capital Raising Investor Presentation
25/11/21	PRICE SENSITIVE	6.5MB	Share
ACW Program Expansion & Capital Raising
25/11/21	PRICE SENSITIVE	271.26KB	Share
ACW Trading Halt
23/11/21	PRICE SENSITIVE	343.76KB	Share
ACW ACW announces open IND for Phase 2 Fragile X trial & LOI
09/11/21	PRICE SENSITIVE	236.09KB	Share
ACW Quarterly Activity Report & Appendix 4C
20/10/21	PRICE SENSITIVE	409.13KB	Share
ACW R&D Tax Incentive Rebate received of A$1.435 million
13/10/21	PRICE SENSITIVE	198.91KB	Share
ACW Actinogen Medical FY21 Results- Progressing the Pipeline
30/08/21	PRICE SENSITIVE	233.75KB	Share
ACW Appendix 4E & Annual Report
30/08/21	PRICE SENSITIVE	2.74MB	Share
ACW Actinogen completes global patent family grant
23/08/21	PRICE SENSITIVE	194.63KB	Share
ACW Quarterly Activity Report & Appendix 4C
22/07/21	PRICE SENSITIVE	284.43KB	Share
ACW First Patient Enrolled in XanaMIA trial
15/07/21	PRICE SENSITIVE	187.34KB	Share
ACW Actinogen receives positive Pre-IND FDA advice for FXS
23/06/21	PRICE SENSITIVE	174.43KB	Share
ACW Clinical progress for XanaMIA trial
21/06/21	PRICE SENSITIVE	137.28KB	Share
ACW Actinogen Ethics Committee approval for XanaMIA study
02/06/21	PRICE SENSITIVE	162.47KB	Share
ACW Response to ASX Price Query
24/05/21	PRICE SENSITIVE	291.5KB	Share
ACW Strategic Update & Teleconference Call Notification
21/04/21	PRICE SENSITIVE	3.02MB	Share
ACW Quarterly Activity Report & Appendix 4C
21/04/21	PRICE SENSITIVE	285.3KB	Share
ACW Actinogen CEO assumes Managing Director position
24/03/21	PRICE SENSITIVE	159.22KB	Share
ACW Actinogen appoints Dr Steven Gourlay as CEO
15/03/21	PRICE SENSITIVE	216.74KB	Share
ACW Appendix 4D & Half-Year Financial Statements
24/02/21	PRICE SENSITIVE	453.53KB	Share

REFRESH

1 2

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 2.8¢		Change 0.001(3.70%)		Mkt cap ! $88.91M

Open	High	Low	Value	Volume
2.8¢	2.9¢	2.8¢	$80.40K	2.835M

Buyers (Bids)

No.	Vol.	Price($)
3	876045	2.8¢

Sellers (Offers)

Price($)	Vol.	No.
2.9¢	238911	3

View Market Depth

No.	Vol.	Price($)
2	821428	0.028
5	2499560	0.027
4	2596470	0.026
14	2431589	0.025
8	2261655	0.024

Price($)	Vol.	No.
0.029	238911	3
0.030	3781464	9
0.031	539999	3
0.032	2534250	7
0.033	981127	8

Last trade - 16.10pm 11/09/2025 (20 minute delay)


Last 2.8¢		Change 0.001 ( 1.82 %)
Open	High	Low	Volume
2.9¢	2.9¢	2.8¢	455728
Last updated 15.53pm 11/09/2025 ?

ACW (ASX) Chart

ACTINOGEN MEDICAL LIMITED - Announcements

Corporate Spotlight

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories